结直肠癌筛查项目中粪便免疫化学检测阳性受检者结肠近端癌症风险
该研究纳入2014-2018年荷兰结直肠癌筛查项目中接受每两年一次粪便免疫化学检测(FIT)的受检者,比较FIT阳性伴进展期肿瘤(AN)、FIT阳性不伴AN与FIT阴性三组在FIT后3年内结肠近端癌症的累积发生率。结果显示三组3年累积发生率分别为0.7%、0.6%和0.4%(P < .001),FIT阳性者结肠近端癌症风险显著增加(HR 1.55,95% CI 1.44-1.67)。
要点
- FIT阳性伴AN组3年结肠近端癌症累积发生率为0.7%,FIT阳性不伴AN组为0.6%,FIT阴性组为0.4%(P < .001)。
- FIT阳性受检者3年内诊断结肠近端癌症的风险显著高于FIT阴性者(HR 1.55,95% CI 1.44-1.67)。
- 尽管风险增加,FIT阳性者3年累积发生率仍低于1%。
核心结论
- FIT阳性受检者在FIT后3年内被诊断结肠近端癌症的风险显著增加,但3年累积发生率仍低于1%。
研究设计与样本
- 研究收集2014-2018年荷兰结直肠癌筛查项目中接受每两年一次FIT筛查的受检者数据,来自国家筛查数据库并链接国家癌症登记库。
- 受检者分为三组:FIT阳性伴AN组(n=65,767)、FIT阳性不伴AN组(n=50,661)和FIT阴性组(n=1,831,647)。
- 采用Cox回归分析(左截断和右删失,以FIT阳性作为时间依赖变量,按性别分层)比较FIT阳性与FIT阴性者结肠近端癌症风险。
主要发现
- FIT阳性伴AN组、FIT阳性不伴AN组和FIT阴性组的3年结肠近端癌症累积发生率分别为0.7%、0.6%和0.4%(P < .001)。
- FIT阳性者较FIT阴性者年龄更大且男性比例更高(P < .001)。
- FIT阳性者结肠近端癌症检出显著多于FIT阴性者(P < .001;HR 1.55,95% CI 1.44-1.67)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In more than half of the colorectal cancer screening participants with a positive fecal immunochemical test (FIT) result, no advanced neoplasia (AN) is detected at colonoscopy. The positive FIT result could also be generated by cancers located proximal to the colon: upper gastrointestinal, oral cavity, nose, and throat cancers. We evaluated screenees' risk of being diagnosed with a cancer proximal to the colon within the 3 years and compared risks between those with a positive vs those with a negative FIT. METHODS: Data of Dutch colorectal cancer screening participants who underwent biennial FIT-based screening 2014-2018 were collected from the national screening database and linked to the National Cancer Registry. Screenees were classified into 3 groups: FIT-positives with AN (FIT+/AN+), FIT-positives without AN (FIT+/AN-), and FIT-negatives (FIT-). We compared the cumulative incidence of cancers proximal to the colon in each group 3 years after FIT. A Cox regression analysis with left truncation and right censoring, using FIT positivity as time-dependent variable and stratified for sex, was performed to compare the hazard of cancers proximal to the colon in participants who were FIT-positive vs FIT-negative. RESULTS: Three-year cumulative incidence of cancers proximal to the colon in FIT+/AN+ (n = 65,767), FIT+/AN- (n = 50,661), and FIT- (n = 1,831,647) screenees was 0.7%, 0.6%, and 0.4%, respectively (P < .001). FIT-positives were older and more frequently male than FIT-negatives (P < .001). Significantly more cancers proximal to the colon were detected among FIT-positives (P < .001; hazard ratio, 1.55; 95% CI, 1.44-1.67). CONCLUSION: FIT-positive screenees were at significantly increased risk of being diagnosed with a cancer proximal to the colon within 3 years after FIT, although the 3-year cumulative incidence was still less than 1%.
引用
- de Klaver W, van der Vlugt M, Spaander MCW, et al. Risk of Cancers Proximal to the Colon in Fecal Immunochemical Test Positive Screenees in a Colorectal Cancer Screening Program. Gastroenterology. 2024. PMID: 38697486. doi:10.1053/j.gastro.2024.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。